Title:
【発明の名称】1,4―二置換ピペラジン
Document Type and Number:
Japanese Patent JPH05509311
Kind Code:
A
Abstract:
A disubstituted piperazine compound having formula (I) wherein R<1> is halogen, methoxy, C1-6-alkyl or trifluoromethyl, and R<2> is methyl or substituted C1-8-alkyl, C3-8-alkenyl or C3-8-cycloalkyl, where substituents may be hydroxy-, keto- or oximino-groups in any position leading to a stable tertiary amine; or R<2> is a straight or branched C1-8-alkyl or C3-8-alkenyl, which in any position may be substituted as above, but is terminally substituted with one of the following groups: cyano, optionally C1-4-alkoxy-substituted C1-4-alkoxy, dimethoxy, optionally substituted phenoxy, phosphonic acid, thienyl, furyl, oxazoline, isoxazole, oxadiazole, where the optional substitution is represented by C1-6-alkyl or phenyl, provided that when cyano is the only substituent in R<2>, R<2> must contain at least four carbon atoms, and pharmaceutically acceptable acid addition salts thereof. The compounds are useful in the treatment of mental disorders in which a dopaminergic deficit is implicated.
Inventors:
Hallweg Rolf
Goodal El Ring
Nielsen Eric Baldrum
Goodal El Ring
Nielsen Eric Baldrum
Application Number:
JP51298491A
Publication Date:
December 22, 1993
Filing Date:
July 15, 1991
Export Citation:
Assignee:
Novo Nordisk Actiesel Scab
International Classes:
A61K31/496; A61K31/66; A61P25/00; A61P25/24; A61P25/26; C07D261/08; C07D261/14; C07D263/10; C07D263/48; A61K31/495; C07D271/06; C07D295/08; C07D295/084; C07D295/088; C07D295/15; C07D307/66; C07D333/20; C07D333/22; C07D333/36; C07F9/38; C07F9/6509; (IPC1-7): C07D261/14; A61K31/495; A61K31/66; C07D263/48; C07D271/06; C07D295/08; C07D307/66; C07D333/36; C07F9/38
Attorney, Agent or Firm:
Minoru Nakamura (6 outside)